T1	HMM 1047 1067	both groups attained
T2	HMM 1224 1235	had greater
T3	HMM 1275 1304	-1.79% (0.05); p = 0.019]
T4	HMM 1418 1531	liraglutide group reported a greater number of gastrointestinal treatment-emergent adverse events (p < 0.001)
T5	HMM 1600 1631	-3.0 (3.6) kg for liraglutide
